Novo’s Nordisk's head of international operations Mike Doustdar was born in Iran, raised in the US and joined the group as an office clerk when a university student in Austria in 1992. Here he tells Scrip how the diabetes fighter's new commercial strategy will work – and why it's targeting a new market, obesity.
Maziar Mike Doustdar faces a big task implementing a new commercial approach under Novo Nordisk AS's new CEO Lars Fruergaard Jørgensen that will give regional centers more business autonomy in effort to remove bureaucracy and centralized rigidities while boosting sales.
Mike Doustdar will be overseeing much of that transition as head of international operations outside North America
Plus deals involving J&J/Addex/Sinntaxis, Concentra/Kronos, Granata/Oviva, Coeptis/Z Squared, Ligand/Channel and more.
PTC said its updated Phase II data for PTC 518 met the primary endpoint of Huntingtin’s protein reduction, but analysts said there isn’t clear correlation with clinical benefit.
The triple therapy improves lung function in the Phase III KALOS and LOGOS studies
Biogen expects little impact from existing tariffs and any that may apply if the US exemption of pharma products is lifted, since 75% of its manufacturing is in the US and 55% of sales are ex-US.
Drugmakers aren’t expecting a big financial hit from tariffs for now, but a report commissioned by PhRMA suggests the cost of pharma-sector tariffs could be steep.
Anil Matai, director general, Organization of Pharmaceutical Producers of India, talks in this audio interview about the evolving intellectual property landscape in India post the 2024 amendments, including long-standing sticking points such as Section 3(d) of India’s patent regulations and innovator firms' experience of the Bolar provision. There’s also a "compelling reason" to consider regulatory data protection, he claims.
Sanofi sold a 50% stake in consumer health unit Opella for €10bn, backing its shift to prescription drugs and funding a €5bn buyback.
